Articles tagged with Vaccination
The VesiVax system uses virus-like particles to induce strong immune responses against various diseases. Dr. Qizhi Cathy Yao is developing better adjuvants for pancreatic cancer and Chagas disease using the system.
Analysis of three types of Zika vaccines reveals they are effective at protecting rhesus monkeys from the virus. The vaccines induce strong antibody responses and provide complete protection against Zika when exposed to the virus.
The National Institute of Allergy and Infectious Diseases has launched a Phase 1 clinical trial to test the safety and ability to generate an immune system response in participants. The investigational DNA vaccine aims to prevent Zika virus infection, which can cause serious birth defects.
A new study by TSRI scientists identifies microRNA-155 as a key player in regulating protein levels and combating disease. The researchers found that miR-155 works by repressing a protein called Peli1, promoting normal T cell proliferation and antibody production.
A recent study of 70,265 Swedish girls and women found that HPV vaccination did not increase the risk of developing another autoimmune disease. Vaccination was associated with a slightly reduced risk compared to not being vaccinated.
Researchers propose that women in Zika-affected countries can safely conceive during the 'trough' of low mosquito activity, reducing the risk of birth defects. This approach could prevent thousands of cases per year, especially in Brazil and Puerto Rico.
Researchers at McMaster University have developed a novel vaccine candidate, BD584, which shows promise in reducing chlamydial shedding and hydrosalpinx by 95% and 87.5%, respectively. The vaccine has the potential to be widely protective against all Chlamydia trachomatis strains, including those causing trachoma.
Researchers at Colorado State University have designed a genetic modification that strips the ability of coxsackievirus B3 to replicate and cause disease. By changing a specific amino acid in the RNA polymerase enzyme, they aim to create a live-attenuated vaccine to protect against this virus and others like it.
A new study from Imperial College London predicts that the current Zika epidemic in Latin America will burn itself out within two to three years due to herd immunity. The team's analysis also concludes that large-scale transmission is unlikely to restart for at least another ten years.
Researchers found that immune checkpoint blockade improved survival and promoted immune cell infiltration into tumors when combined with an antitumor vaccine. The study suggests PD-1 and PD-L1 may help tumors evade vaccines, supporting testing of therapeutic combinations in clinical trials.
A new study published in the Canadian Medical Association Journal found that HPV vaccination programs can reduce cervical cell anomalies in young women. The study showed that 3-dose HPV vaccination has demonstrated early benefits against high-grade cervical abnormalities, which are more likely to progress to cervical cancer.
A new E. coli-based transport capsule has been developed to improve the efficiency of next-generation vaccines, with promising results in fighting pneumococcal disease. The capsule uses a harmless strain of E. coli wrapped in a synthetic polymer to deliver antigens and trigger an immune response.
Researchers at Kansas State University's Biosecurity Research Institute are studying the relationship between Zika virus and mosquitoes to develop better controlling methods. They aim to target specific species of mosquitoes that transmit the virus, such as Aedes aegypti and Aedes albopictus, which are widely distributed in the U.S.
A vaccine developed by Brazilian and US researchers has been successfully tested in mice trials, preventing viral replication and inducing a protective immune response. The vaccine targets the premembrane protein and external envelope protein of Zika virus, offering hope for humans in the near future.
A new study published in Nature demonstrates complete protection against the Zika virus in mice using two different vaccine candidates. The researchers showed that a single dose of either a DNA vaccine or a purified inactivated virus vaccine provides complete protection, similar to existing vaccines for other flaviviruses.
A new preclinical study suggests that an effective Zika vaccine is achievable. Two vaccine candidates were tested and found to be safe and protective against the virus in mice. The purified inactivated virus (PIV) vaccine is being developed and planned for human testing later this year.
Two experimental Zika vaccines fully protected mice from infection, even after four weeks without inoculation. The DNA and inactivated virus vaccines induced virus-specific antibodies, correlating with protection against infection.
A new anthrax capsule vaccine has been found to completely protect monkeys from lethal inhalational anthrax infection. The study suggests that the capsule is a highly effective vaccine component that could be incorporated into future generation anthrax vaccines, offering a safer alternative to existing protective antigen-based vaccines.
Researchers have discovered two antibodies that can efficiently neutralize both dengue and Zika viruses, sharing identical binding sites on their viral envelopes. This breakthrough could lead to the development of a single vaccine offering protection against both diseases.
Saint Louis University is conducting a human clinical trial of a Zika virus vaccine to prevent microcephaly and brain damage in babies. The study aims to protect people from the emerging infectious disease, which can be transmitted through mosquito bites or sexual contact.
A phase II clinical trial showed that GEN-003 immunotherapy significantly reduces genital herpes virus activity and recurrent outbreaks, lasting up to a year after treatment. This new approach may provide relief similar to daily antiviral medications but with improved convenience.
A study published in PLOS NTDs examined the immune response to a bivalent whole cell oral cholera vaccine in Haitian adults. The researchers found that the booster dose after 2 weeks did not stimulate the immune system further, suggesting an optimal dosing schedule may be needed.
Researchers found that combining local radiation therapy with anti-cancer vaccines can increase the response rate for immunotherapy agents by boosting T cell infiltration into tumors. This combination may help physicians better treat many types of cancer and could potentially lead to improved outcomes.
Researchers found that open communication about vaccine safety through VAERS did not increase public trust in vaccines. In fact, detailed incident reports significantly reduced vaccine acceptance and trust. The study suggests the media should be cautious when sharing stories about vaccine harms to avoid influencing public perception.
Researchers monitored social media in real-time to identify Zika conspiracy theories that could be affecting people's health-related decisions. The study found nearly 140,000 Tweets with keywords 'vaccine' and 'Zika,' highlighting the need for public health authorities to address concerns and debunk unscientific claims.
The WHO has convened an emergency committee due to the risk of a YF outbreak in unvaccinated populations in Asia. The World Health Organization is concerned about the limited supply of vaccine, but experts warn that this poses a strong risk of epidemics.
The George Washington University School of Medicine and Health Sciences is conducting a phase 1 clinical trial to test a hookworm vaccine in an endemic area of Brazil. The trial aims to determine the safety and efficacy of combining two existing vaccines, with potential implications for global health.
A review article by J. David Beckham highlights Zika virus's impact on global health, emphasizing the need for ongoing research to develop a viable vaccine and treatment options. The article notes that exposure avoidance through insect repellent and protective measures is currently the best approach to prevent complications.
A new approach using a two-minute video has been shown to boost pneumococcal vaccination rates among older adults, with 64% watching the entire video and receiving the vaccine. The study found that patients who viewed at least part of the video were three times more likely to receive the vaccine.
Immunizing babies against rotavirus led to a significant drop in hospitalizations and emergency department visits. The study found that even older kids benefited from the vaccination, demonstrating herd immunity.
Two patients with liver metastasis from melanoma survived for at least 8.5 and 12 years after receiving patient-specific immunotherapeutic vaccines. The vaccines were derived from the patients' own dendritic cells loaded with proteins isolated from their tumors. Co-Editor-in-Chief Donald J. Buchsbaum, PhD, describes these results as
A global health emergency is looming due to the rapid spread and potential future outbreaks of yellow fever, say Georgetown University professors. The ongoing epidemic, particularly in Angola, has led to a significant shortage of vaccines and calls for an urgent international response.
A study found that vaccination under the influence of estradiol enhances protection against genital herpes by shifting the immune response in the vaginal mucosa toward a more effective antiviral one. Estradiol accelerates and increases the response of T helper cells, promoting inflammation.
The study found significant improvements in up-to-date vaccination rates, with a 7% increase from 75% to 82%. Over-immunization for adolescents also decreased significantly. The data exchange allowed clinicians to easily access patient immunization information, reducing the likelihood of unnecessary vaccinations.
A study suggests that current vaccines provide only partial protection against the G5 strain of Japanese encephalitis virus, and natural infection with a different strain may not offer protection. The findings indicate that an emerging crisis in South-East Asia is possible, warranting further research on vaccines.
A new study finds HPV vaccination is expected to reduce cancer burden across all racial/ethnic groups, with some disparities persisting despite high vaccine uptake. The study suggests that efforts to improve vaccine uptake must be accompanied by efforts to address access issues for screening and timely diagnoses.
Global norovirus experts identify key gaps in knowledge and provide information to further vaccine development. The most efficient approach is developing a vaccine for young children, with the greatest impact at the global level.
A recent study published in eLife reveals that novel swine flu viruses have emerged, driven by the frequent introduction of human viruses to pigs. The analysis of nearly 600 flu viruses from multiple continents shows a high level of antigenic diversity, posing a significant risk to human health.
HPV vaccination programs in Canada are currently limited, leaving men vulnerable to HPV-related diseases. The Canadian Medical Association Journal recommends expanding the programs to include males and negotiating with pharmaceutical companies to decrease costs.
Experts argue that good governance, long-term technology investment, and strong product management skills are essential to combat infectious outbreaks. The proposed global strategy aims to pool funds and coordinate efforts to develop effective countermeasures for these diseases.
A new study reveals that laboratory mice infected with common human viruses develop an immune system similar to newborn humans, but unlike adult humans. This finding suggests that the lack of infection may be a reason why research mice differ from humans.
A new mouse model developed by researchers at the University of Wisconsin-Madison School of Veterinary Medicine enables the study of Zika virus infection and its effects on the brain. The model, which lacks key immune system components, allows for the testing of vaccines and antivirals against the virus.
A phase 1 trial evaluated two candidate Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo, in healthy volunteers. The study found that immunization with Ad26.ZEBOV generated an initial immune response and sustained elevation of specific immunity, suggesting partial protection against Ebola.
An immunization regimen using two Ebola vaccine candidates was found to be safe and well-tolerated, inducing an immune response in healthy adult volunteers. The study's results suggest that the vaccines could provide durable protection against Ebola, which is essential for areas with intermittent outbreaks.
Scientists at the University of Wisconsin-Madison have created a mouse model to study Zika virus, allowing researchers to test vaccines and antivirals while understanding the virus's effects on human brains. The model, lacking key immune system defenses, shows the virus causes severe pathology in brain tissue.
A new HPV vaccine could significantly reduce cervical cancer incidence by 73% and healthcare costs if states coordinate policies to improve coverage. Increased funding can lead to improved vaccine coverage and public health.
Scientists at Oxford University have identified biomarkers that could indicate TB risk and provide clues to assess the effectiveness of potential new vaccines. The discovery was made using immune correlates, also known as biomarkers, which can be measured in the blood.
A mobile-phone-based system is demonstrating huge potential for improving public health service delivery in resource-poor settings. The system has facilitated ongoing data collection, greatly improving data quality, timeliness, and cost-effectiveness.
A recent study found that HPV vaccination stimulates robust immune responses in girls and young women with chronic kidney disease and dialysis, but less optimal responses among those with a kidney transplant. This highlights the need for additional research to protect kidney transplant recipients from HPV infections.
A vaccine developed for smallpox improved lung function in a mouse model of idiopathic pulmonary fibrosis by inducing resident memory CD4+ T cells. This immune response was associated with reduced fibrosis and increased survival rates.
Researchers at McMaster University have identified a critical step in the immune system's recognition of DNA viruses, which could lead to vaccinations for herpes, the common cold, and even cancer. The discovery involves an interaction between proteins S6K1 and STING that triggers antiviral responses.
The NIH has awarded six grants to study the molecular mechanisms behind combination vaccine adjuvants, which improve vaccine effectiveness and could lead to new treatments for diseases like HIV and tuberculosis. Researchers will explore how individual adjuvants work in combination and how synergies between them can be optimized.
A novel vaccine strategy has been developed to provide both short-term and long-term protection against the Chikungunya virus. The strategy combines a non-viral, vector-based monoclonal antibody delivery method with a DNA-based vaccine approach.
Researchers at UTMB have developed a new mouse model for Zika infection, removing a bottleneck in preclinical testing. The model is available for immediate screening of antivirals and vaccine candidates.
A team of UCI scientists led by Philip Felgner has received $8 million to develop a new vaccine for Q fever, a highly infectious agent considered a potential bioterrorism weapon. The vaccine aims to mitigate severe side effects of the current vaccine and is expected to be safer and more effective.
Researchers at Oregon Health & Science University recommend revisiting current adult vaccination schedule due to long-lasting immunity against tetanus and diphtheria. A revised 30-year schedule could reduce healthcare costs by two-thirds, saving approximately $280 million annually.
A new study found that conflicting expectations between parents and medical providers about scheduling follow-up appointments is the most common reason for patients not completing the HPV vaccine series. Researchers suggest improving education and dialogue between providers and parents to increase vaccination completion rates.
Researchers analyzed numerous studies and reports to find that unvaccinated individuals comprised a substantial proportion of cases in measles and pertussis outbreaks. Vaccine refusal was associated with an elevated risk for measles and pertussis, even among fully vaccinated individuals.
Researchers from Penn Medicine warn that labelling public health initiatives as 'natural' could lead to harmful decision-making by some parents. They argue that this messaging undermines important health practices, such as childhood vaccination.
Researchers developed a nanoparticle technology called Salipro to stabilize membrane proteins in a lipid environment, allowing for high-resolution studies of their structure and function. This enables the discovery of new drugs, therapeutic antibodies, and vaccines targeting these proteins.